Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer, October 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 128 articles: HTML format

Single Articles

1. WU S, Fu S, Shi H, Gong Y, et al
   Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies.
   Front Immunol. 2026;17:1920567.
   PubMed    
   Abstract available
   
   

2. ERMIS O, Aybal HC, Yuan CY, Tozsin A, et al
   Simultaneous surgery for NMIBC and BOO: evaluating surgical safety to oncological benefit.
   Minerva Urol Nephrol. 2026;78:484-497.
   PubMed    
   Abstract available
   
   

3. SCILIPOTI P, Slusarczyk A, Subiela JD, Longoni M, et al
   Surrogacy of intermediate clinical endpoints for overall survival in BCG-naive high-risk non-muscle-invasive bladder cancer.
   World J Urol. 2026;44:721.
   PubMed    
   Abstract available
   
   

4. ELMASMOUDI J, Merseburger AS
   Circulating tumour DNA and extrachromosomal DNA in prostate and bladder cancer: biology, clinical applications and future perspectives.
   World J Urol. 2026;44:722.
   PubMed    
   Abstract available
   
   

5. SCHOLTES MP, Koedoot E, Ceton LJ, Sijsenaar TJP, et al
   Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer.
   Eur Urol Open Sci. 2026;93:3-11.
   PubMed    
   Abstract available
   
   

6. HAU AM, Nakasaki M, Nakashima K, Krish G, et al
   Corrigendum to "Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition" Volume 35, Issue 10, October 2017, Pages 593-599.
   Urol Oncol. 2026 Oct 1:S1078-1439(26)00729-5. doi: 10.1016/j.urolonc.2026.
   PubMed    
   
   
   

7. CLARK PE
   Management of Muscle-Invasive Bladder Cancer.
   Urol Clin North Am. 2026;53:xv.
   PubMed    
   
   
   

8. LOUGHLIN KR
   Muscle-Invasive Bladder Cancer: The Marriage of Surgery and Science.
   Urol Clin North Am. 2026;53:xiii-xiv.
   PubMed    
   
   
   

9. SUPERDOCK M, Iyer G, Milowsky MI
   New and Novel Agents for Advanced Bladder Cancer.
   Urol Clin North Am. 2026;53:635-648.
   PubMed    
   Abstract available
   
   

10. ROESSLER N, von Deimling M, Miszczyk M, Vetterlein MW, et al
    The Role of Surgery in Locally Advanced and Oligometastatic Bladder Cancer.
    Urol Clin North Am. 2026;53:625-634.
    PubMed    
    Abstract available
    
    

11. DUBIC MG, Ward MC, Riggs S
    Trimodal Therapy for Muscle Invasive Bladder Cancer: An Update on Current Practices and Future Directions.
    Urol Clin North Am. 2026;53:613-624.
    PubMed    
    Abstract available
    
    

12. ZHU A, Eraky A, Gabriel PE, Sfakianos JP, et al
    The Role of Biomarkers in the Management of Muscle-Invasive Bladder Cancer.
    Urol Clin North Am. 2026;53:601-612.
    PubMed    
    Abstract available
    
    

13. ATIQ SO, Miller EJ, Anker JF, Galsky MD, et al
    Adjuvant Therapy in Patients after Cystectomy.
    Urol Clin North Am. 2026;53:593-600.
    PubMed    
    Abstract available
    
    

14. MCSWEENEY ST, Aydogdu C, Bole R, Bukavina L, et al
    Sexual Function Preservation After Cystectomy.
    Urol Clin North Am. 2026;53:571-582.
    PubMed    
    Abstract available
    
    

15. GHASEMZADEH A, Bochner BH
    What Is the Proper Extent of Lymph Node Dissection During a Radical Cystectomy for Bladder Cancer?
    Urol Clin North Am. 2026;53:561-569.
    PubMed    
    Abstract available
    
    

16. SADIQ S, Nativ O, Ritch CR
    Open and Robotic Radical Cystectomy for Muscle-Invasive Bladder Cancer: Techniques, Outcomes, and Evidence.
    Urol Clin North Am. 2026;53:551-559.
    PubMed    
    Abstract available
    
    

17. CHUNG R, Zibelman MR, Wong JK, Kutikov A, et al
    Advancements in Bladder-Sparing Strategies for Muscle-Invasive Bladder Cancer: A Comprehensive Review.
    Urol Clin North Am. 2026;53:539-549.
    PubMed    
    Abstract available
    
    

18. BRITTON CJ, Galloway LAS, Luckenbaugh AN
    Prehabilitation and Patient Optimization for Cystectomy.
    Urol Clin North Am. 2026;53:527-538.
    PubMed    
    Abstract available
    
    

19. EBER J, Matulay JT
    Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: Current Evidence, Evolving Strategies, and Future Directions.
    Urol Clin North Am. 2026;53:517-526.
    PubMed    
    Abstract available
    
    

20. ERNANDEZ J, Xiang L, Adler R, Hsu J, et al
    Significance of dementia and frailty on postoperative care trajectories and burden among older adults undergoing radical cystectomy for bladder cancer.
    J Geriatr Oncol. 2026;18:104389.
    PubMed    
    Abstract available
    
    

21. LI R, Linscott J, Murthy P, Rose K, et al
    Evaluation of Urinary Circulating Tumor DNA to Detect Minimal Residual Disease in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.
    medRxiv [Preprint]. 2026 Sep 11:2026.09.09.26362655.
    PubMed    
    Abstract available
    
    

22. DEITER CS, de Jong FC, Olislagers M, Jordan KR, et al
    Stromal innervation is prognostic in non-muscle-invasive bladder cancer and predicted by a distinct microenvironmental transcriptomic signature.
    bioRxiv [Preprint]. 2026 Sep 22:2026.09.21.751588.
    PubMed    
    Abstract available
    
    

23. SOMEYA R, Tanaka E, Yamazak M, Yokoi T, et al
    [URINARY RETENTION FOLLOWING TRANSURETHRAL RESECTION OF THE BLADDER TUMOR].
    Hinyokika Kiyo. 2026;72:269-271.
    PubMed    
    Abstract available
    
    

24. SHAIKH AN, Ginayatova I, Malikova I, Kriajevska M, et al
    Novel Approaches in Bladder Cancer Diagnosis and Treatment.
    Curr Med Chem. 2026 Sep 29. doi: 10.2174/0109298673474262260909061628.
    PubMed    
    Abstract available
    
    

25. ASLAM N, Kafagi AH, Khela A, Montague R, et al
    Metastatic muscle invasive bladder cancer in pregnancy.
    BMJ Case Rep. 2026;19:e275274.
    PubMed    
    Abstract available
    
    

26. FRISCH D, Fronstin M, Zema C
    Agentic AI for Clinical Outcomes Research, Population Health Management Analyses With Large Administrative Databases, and Generating Epidemiological Estimates of Diseases: Feasibility and Validation Study.
    J Med Internet Res. 2026;28:e100284.
    PubMed    
    Abstract available
    
    

27. MORGAN TM, Wang CY, Yapici HO, Lilley J, et al
    Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy.
    Urol Oncol. 2026;44:960-967.
    PubMed    
    Abstract available
    
    

28. WU Y, Han W, Xiong S, He Y, et al
    Urine Methylation Test for Urothelial Cancer Diagnosis and Surveillance.
    JAMA Netw Open. 2026;9:e2636786.
    PubMed    
    Abstract available
    
    

29. ZHANG M, Chen Z, Chen Y, Zhou Y, et al
    Longitudinal data on health-related quality of life and its association with time to readmission in bladder perfusion patients.
    Support Care Cancer. 2026;34:1032.
    PubMed    
    Abstract available
    
    

30. JAMBALE U, Thimmappa SC
    Phytochemical Profiling, Antioxidant Activity and Cytotoxic Potential of Chloroxylon swietenia DC. Stem Extracts Against Bladder Cancer Cell Lines.
    Biomed Chromatogr. 2026;40:e70616.
    PubMed    
    Abstract available
    
    

31. MOHAMMED MS, Abouhashim NS, Elfeky MA
    Evaluation of GATA3 and HER-2 Immunohistochemical Expression as Prognostic Markers in Urothelial Carcinoma of the Urinary Bladder.
    Asian Pac J Cancer Prev. 2026;27:3273-3279.
    PubMed    
    Abstract available
    
    

32. LUO H, Liu X, Du Y
    Cascade Catalytic Nanozyme Amplifies Ferroptosis Immunotherapy in Bladder Cancer.
    J Biomed Mater Res A. 2026;114:e70164.
    PubMed    
    Abstract available
    
    

33. LINGEFELT S, Nystrand V, Alamdari F, Svensson J, et al
    No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer.
    Scand J Urol. 2026;61:230-238.
    PubMed    
    Abstract available
    
    

34. ZHU Y, Shang J, Zhang X, Tu S, et al
    Urine-derived induced pluripotent stem cells for non-invasive diagnosis of bladder cancer.
    J Cancer. 2026;17:1720-1732.
    PubMed    
    Abstract available
    
    

35. GOUNNI MY, Bourimi C, Tariqi R, Bakouch M, et al
    A false alarm in bladder cancer surveillance: eosinophilic cystitis after intravesical BCG instillations.
    J Surg Case Rep. 2026;2026:rjag855.
    PubMed    
    
    
    

36. LI S, Peng H, Li G, Wan Z, et al
    A candidate PPARgamma to GPX4 axis in ferroptosis suppression and platinum resistance in bladder cancer: evidence appraisal and a testable research agenda.
    J Cancer. 2026;17:1797-1807.
    PubMed    
    Abstract available
    
    

37. LI J, Tang C, Yang L, Song C, et al
    ctDNA- and cfDNA-based liquid biopsy in bladder cancer and urothelial carcinoma: bibliometric mapping and cross-database coverage analysis, 2008-2025.
    Front Oncol. 2026;16:1906152.
    PubMed    
    Abstract available
    
    

38. MAO D, Chen R, Guan F, Sun J, et al
    Prognostic value of systemic inflammatory response index in patients with bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1876253.
    PubMed    
    Abstract available
    
    

39. ACQUISTAPACE E, Bernardini B, Piccioni F, Pastore M, et al
    Exploring the Role of the Nurse Case Manager in the Care Experience of Patients Undergoing Radical Cystectomy: A Qualitative Study.
    Nurs Open. 2026;13:e70821.
    PubMed    
    Abstract available
    
    

40. BIEST AMD, Xylinas E, Gabriel PE
    SEQUENTIAL INTRAVESICAL GEMCITABINE-DOCETAXEL AFTER BCG FAILURE NON-MUSCLE INVASIVE BLADDER CANCER: ONCOLOGICAL OUTCOMES AND SAFETY PROFILE.
    Fr J Urol. 2026 Sep 28:103229. doi: 10.1016/j.fjurol.2026.103229.
    PubMed    
    Abstract available
    
    

41. STOJKOVA O, Borcsok J, Sztupinszki Z, Diossy M, et al
    Identification of an ERCC2 Mutation-Associated Mutational Signature of Nucleotide Excision Repair Deficiency in Targeted Panel Sequencing Data.
    JCO Precis Oncol. 2026;10:e2600329.
    PubMed    
    Abstract available
    
    

42. HEER R, Farrokhi M
    Global trends and hotspots in bladder cancer: A bibliometric analysis (2016-2025).
    Urologia. 2026 Sep 28:3915603261483766. doi: 10.1177/03915603261483766.
    PubMed    
    Abstract available
    
    

43. DING W, Zhang X, Wu H, Zhou C, et al
    Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment.
    Int J Nanomedicine. 2026;21:616713.
    PubMed    
    Abstract available
    
    

44. 
    Correction to "Gut Parabacteroides distasonis-Derived Indole-3-Acetic Acid Promotes Phospholipid Remodeling and Enhances Ferroptosis Sensitivity via the AhR?FASN Axis in Bladder Cancer".
    Adv Sci (Weinh). 2026 Sep 27:e77485. doi: 10.1002/advs.77485.
    PubMed    
    
    
    

45. WANG L, Liu X, Zhu T, Su Z, et al
    Isocyanate-Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3-Mediated Extracellular Matrix Remodeling and cGAS-STING Pathway Activation in Bladder Cancer.
    Adv Sci (Weinh). 2026 Sep 27:e77833. doi: 10.1002/advs.77833.
    PubMed    
    Abstract available
    
    

46. NAKANISHI Y, Kawashima Y, Shinohara M, Hagiwara K, et al
    Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report.
    IJU Case Rep. 2026;9:e70270.
    PubMed    
    Abstract available
    
    

47. GONTERO P, Babjuk M
    Reply to Roberto M. Scarpa's Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Exp
    Eur Urol Oncol. 2026 Sep 26:S2588-9311(26)00243.
    PubMed    
    
    
    

48. MANTZ L, Zhu A, Mercaldo ND, Marquardt PA, et al
    Novel use of computed tomography-derived body composition to facilitate risk assessment in patients with bladder cancer.
    Urol Oncol. 2026;44:946-959.
    PubMed    
    Abstract available
    
    

49. ERYILMAZ R, Keles MF, Aslan R, Huyut Z, et al
    Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.
    Urol Oncol. 2026;44:939-945.
    PubMed    
    Abstract available
    
    

50. KAUR N, Aravind A, Jain SP
    Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature.
    J Hematop. 2026;19:59.
    PubMed    
    Abstract available
    
    

51. JI Y, Zhang Y, Liu X, Lv Z, et al
    Single-cell and bulk transcriptomic analyses define an IFI27-centered interferon-response epithelial state in bladder cancer and its transcriptional response to irradiation.
    Front Cell Dev Biol. 2026;14:1920354.
    PubMed    
    Abstract available
    
    

52. WU X, Sun T, Liu Z
    Identification and experimental validation of prognostic genes associated with dietary restriction-related signatures in bladder cancer.
    Front Immunol. 2026;17:1891824.
    PubMed    
    Abstract available
    
    

53. TICHIL BP, Besleaga A, Gheorghiu I, Chiorean AD, et al
    Paired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Study.
    J Clin Med. 2026;15:7117.
    PubMed    
    Abstract available
    
    

54. PALACKA P, Kovacova Ilijew H, Mikolaskova I, Suchankova M, et al
    The Role of Circulating Extracellular DNA in Patients with Bladder Cancer: Clinical Associations and Exploratory Links with Heart Rate Variability.
    Cancers (Basel). 2026;18:2952.
    PubMed    
    Abstract available
    
    

55. TATAR AC, Voidazan S, Raicea A, Popelea MC, et al
    Immunohistochemistry-Based Molecular Classification of Muscle-Invasive Bladder Urothelial Carcinoma: Survival Trends Across Molecular Subtypes.
    Int J Mol Sci. 2026;27:8082.
    PubMed    
    Abstract available
    
    

56. BILYALOV A, Kotov A, Bodunova N, Zingerenko M, et al
    Molecular Classifications and Candidate Biomarkers for Personalizing BCG Therapy in Non-Muscle-Invasive Bladder Cancer.
    Biomedicines. 2026;14:2098.
    PubMed    
    Abstract available
    
    

57. SZACHNIEWICZ M, Baran M, Gagat M, Halas-Wisniewska M, et al
    Preliminary Evaluation of SGLT2 Inhibitors in Human Bladder Cancer T24 Cells.
    Biomedicines. 2026;14:2037.
    PubMed    
    Abstract available
    
    

58. SAITO R, Sano T, Kanno T, Aizawa R, et al
    Clinical indications and implications of metastasis-directed therapy and primary-site treatment in metastatic urothelial carcinoma.
    Int J Clin Oncol. 2026;31:2114-2125.
    PubMed    
    Abstract available
    
    

59. ERAKY A, Mehrazin R, Tillu N, Wagaskar VG, et al
    The Hood Technique for Robot-Assisted Radical Cystoprostatectomy with Intracorporeal Neobladder.
    J Endourol. 2026;40:1156-1163.
    PubMed    
    Abstract available
    
    

60. ZHANG K, Li H, Ma Z, Yu Y, et al
    Metabolic Reprogramming by Engineered Probiotics Potentiates Tumor Chemodynamic Immunotherapy.
    Adv Mater. 2026;38:e74353.
    PubMed    
    Abstract available
    
    

61. ASLAN S, Eryuruk U, Park SY, Arita Y, et al
    VI-RADS and beyond in bladder MRI: a pictorial review of quality control, response assessment, and artificial intelligence.
    Eur J Radiol. 2026;204:113114.
    PubMed    
    Abstract available
    
    

62. HUANG W, Fu W, Zhang X, Sun H, et al
    Validation and predictive modeling of a portable bladder scanner for precision bladder management in pelvic radiotherapy.
    Br J Radiol. 2026;99:2155-2163.
    PubMed    
    Abstract available
    
    

63. CONTIERI R, Gontero P, Hurle R, Afferi L, et al
    Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.
    Nat Rev Urol. 2026;23:691-696.
    PubMed    
    Abstract available
    
    

64. ROESSLER N, Miszczyk M, Miyajima K, Alfarhan AR, et al
    The Influence of Urinary Diversion Type on Body Image and Decision Regret Following Radical Cystectomy: A Systematic Review.
    Eur Urol Focus. 2026;12:785-795.
    PubMed    
    Abstract available
    
    

65. MAIORANO BA, Necchi A
    Indirect comparison of reconstructed individual patient data from KEYNOTE-905/EV-303 and PURE-01: complementary analyses for interpreting event-free survival in muscle-invasive bladder cancer.
    ESMO Open. 2026;11:108597.
    PubMed    
    Abstract available
    
    

66. ROSHANSHAD A
    Advanced Diffusion MRI-based MR Cytometry for Quantitative Microstructural Assessment and Grading of Bladder Cancer.
    Radiol Imaging Cancer. 2026;8:e269023.
    PubMed    
    
    
    

67. SHI L, Chen C, Li L, Chen J, et al
    Effects of Acupoint Application on Lower Urinary Tract Symptoms in Patients Undergoing Intravesical Instillation After Bladder Cancer Surgery: A Randomized Crossover Exploratory Study.
    Pain Res Manag. 2026;2026:e5079749.
    PubMed    
    Abstract available
    
    

68. 
    Correction to "MMP9 Knockout by CRISPR-Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti-PD-L1 in an Orthotopic Mouse Model".
    IUBMB Life. 2026;78:e70134.
    PubMed    
    
    
    

69. KIM MS, Lim DG, Jung SI, Hwang EC, et al
    Screening Bacteriuria Using the Sysmex UF-5000 during Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer.
    Chonnam Med J. 2026;62:99-106.
    PubMed    
    Abstract available
    
    

70. BAI M, Liu T, Wu H, Yang X, et al
    IGF2BP2 remodels the lung metastatic immune microenvironment to promote bladder cancer metastasis.
    Cell Mol Immunol. 2026 Oct 9. doi: 10.1038/s41423-026-01474.
    PubMed    
    Abstract available
    
    

71. YEOM JY, Kim YU, Kim J, Min J, et al
    Effect of nefopam on postoperative catheter-related bladder discomfort after transurethral resection of the bladder under general anesthesia: A randomized controlled trial.
    J Int Med Res. 2026;54:3000605261495728.
    PubMed    
    Abstract available
    
    

72. VAEZI A, Mossavarali S, Raznahan M, Haddad M, et al
    Log Odds of Positive Lymph Nodes as a Novel Prognostic Predictor for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2026 Sep 21:102664. doi: 10.1016/j.clgc.2026.102664.
    PubMed    
    Abstract available
    
    

73. GUZMAN T, McSweeney S, Aydogdu C, Diaz G, et al
    Nonmuscle-invasive bladder cancer after solid organ transplantation: Clinical outcomes and recurrence patterns.
    Urol Oncol. 2026 Oct 8:S1078-1439(26)00713-1. doi: 10.1016/j.urolonc.2026.
    PubMed    
    Abstract available
    
    

74. ZUGMAN M, Kirche Duarte I, Baccaglini W
    The cost of intensification in high-risk non-muscle-invasive bladder cancer.
    ESMO Open. 2026;11:108598.
    PubMed    
    
    
    

75. QIE Y, Jia K, Huang S, Zhao J, et al
    Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2026 Oct 8. doi: 10.1001/jamaoncol.2026.3909.
    PubMed    
    Abstract available
    
    

76. GENG H, Wu Y, Ma J, Zhang W, et al
    Exosomal circ55033 promotes cigarette smoke-induced bladder cancer by modulating EMT and stem cell properties.
    Med Oncol. 2026;43:326.
    PubMed    
    Abstract available
    
    

77. GORE JL, Thompson A, Kelkar SS, Chirikov V, et al
    Characteristics and Treatment Patterns of Patients with Muscle-Invasive Bladder Cancer in the United States: A Real-World Cohort Study.
    Pragmat Obs Res. 2026;17:617060.
    PubMed    
    Abstract available
    
    

78. JEONG JI, Lee J, Oh MH, Cho HD, et al
    MITF-Overexpressing Perivascular Epithelioid Cell Tumor of the Urinary Bladder Lacking TSC1/TSC2 Alterations and TFE3 Rearrangement: A Case Report and Review of the Literature.
    Pathol Int. 2026;76:e70187.
    PubMed    
    Abstract available
    
    

79. FU S, Tan Z, Shi H, Chen J, et al
    Retraction Note: Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.
    NPJ Precis Oncol. 2026;10:377.
    PubMed    
    
    
    

80. ZHANG XZ, Xiang JA, Yang LC, Li YD, et al
    Traditional Chinese medicine in non-muscle-invasive bladder cancer: a scoping review of syndrome characteristics and critical synthesis of pharmacological and mechanistic evidence.
    Front Pharmacol. 2026;17:1921622.
    PubMed    
    Abstract available
    
    

81. WANG H, Liu H, Ma X, Wang W, et al
    Structure-based virtual screening identifies ethyl rosmarinate as a SLC1A6-targeted therapeutic candidate for bladder cancer.
    Front Pharmacol. 2026;17:1895264.
    PubMed    
    Abstract available
    
    

82. LI S, Zhang Y, Mao T, Wei J, et al
    Aromatic amine exposure and bladder cancer: a review of recent advances in epidemiology, pathogenesis, and prevention.
    Front Cell Dev Biol. 2026;14:1914792.
    PubMed    
    Abstract available
    
    

83. RAGGI D, Crupi E, Dyrskjot L
    ctDNA in muscle-invasive bladder cancer - clinically actionable, not yet standardized.
    Nat Rev Urol. 2026 Oct 6. doi: 10.1038/s41585-026-01197.
    PubMed    
    
    
    

84. CRONIN C, Lokeshwar SD, Calagua C, Garman TS, et al
    Adamantinoma-like Ewing sarcoma of the bladder.
    BMJ Case Rep. 2026;19:e270671.
    PubMed    
    Abstract available
    
    

85. MOCHIZUKI T, Ishiguro Y, Takeshima T, Hashizume A, et al
    Elevated expression of olfactory receptor 51T1 is associated with malignant potential of bladder cancer.
    Cancer Treat Res Commun. 2026;49:101467.
    PubMed    
    Abstract available
    
    

86. ZENGERLING F
    [Blue versus white light during transurethral resection of nonmuscle invasive bladder cancer].
    Urologie. 2026 Oct 6. doi: 10.1007/s00120-026-02938.
    PubMed    
    
    
    

87. PENG Z, Jia R, Zhang T, Yang J, et al
    CNOT4 Suppresses Bladder Cancer Progression by Promoting Ubiquitination-Mediated Degradation of EIF2AK2 and Inhibiting Autophagy.
    Mol Carcinog. 2026 Oct 6. doi: 10.1002/mc.70187.
    PubMed    
    Abstract available
    
    

88. ZHU K, Zhang Y, Wang Y, Chen L, et al
    Shared decision-making experiences regarding urinary diversion among Chinese patients with muscle-invasive bladder cancer: A qualitative study.
    Asia Pac J Oncol Nurs. 2026;13:101024.
    PubMed    
    Abstract available
    
    

89. ENGELS EA, Burkett S, Ramanujan VK, Yu KJ, et al
    Donor-derived bladder cancer following kidney transplantation.
    Urol Case Rep. 2026;69:103618.
    PubMed    
    Abstract available
    
    

90. DU T, She Y, Li H, Liu X, et al
    Active bacteria-delivered nanosystems for multimodal bladder cancer therapy.
    Sci Bull (Beijing). 2026 Sep 22:S2095-9273(26)01178.
    PubMed    
    
    
    

91. MATHISEN IF, Koll FJ, Mayer RS, Schulz MH, et al
    Dual-Foundation-Model Ensemble Predicts Gene Expression in Muscle-Invasive Bladder Cancer for Patient Outcome Stratification.
    Mod Pathol. 2026 Oct 5:101092. doi: 10.1016/j.modpat.2026.101092.
    PubMed    
    Abstract available
    
    

92. PYRGIDIS N, Engelmann P, Puhr-Westerheide D, Ebner B, et al
    The effect of ureteral stenting on the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors involving the ureteral orifice.
    World J Urol. 2026;44:725.
    PubMed    
    Abstract available
    
    

93. WEI B, Liu T, Chang X, Guo L, et al
    Celastrol Sensitizes Bladder Cancer to Gemcitabine by Regulating LINC00839-Mediated Homologous Recombination DNA Repair.
    Biochemistry (Mosc). 2026;91:1704-1715.
    PubMed    
    Abstract available
    
    

94. YANG Y, Han L, Li J, Xue J, et al
    Social alienation among people with bladder cancer: A combined structural equation modeling and fuzzy-set qualitative comparative analysis.
    Asia Pac J Oncol Nurs. 2026;13:101025.
    PubMed    
    Abstract available
    
    

95. XU X, Hao HY, Chen HY
    The clinical landscape of bladder cancer treatment: a brief report on new developments and future perspectives in pharmaceutical interventions.
    Front Oncol. 2026;16:1747070.
    PubMed    
    Abstract available
    
    

96. SHI G, Wu Y, Wang Y, Wang S, et al
    The deubiquitinating enzyme UCHL3 promotes bladder cancer progression and glycolysis through enhancing PKM2 protein stability.
    Front Oncol. 2026;16:1883763.
    PubMed    
    Abstract available
    
    

97. LIU KJ, Shi WY, Nesselbush MC, Phillips NA, et al
    Urine cell-free RNA for bladder cancer detection and treatment response prediction.
    Nat Med. 2026 Oct 2. doi: 10.1038/s41591-026-04673.
    PubMed    
    Abstract available
    
    

98. ZARKA J, Childs DS, Muniz Rincon M, Tarhini A, et al
    Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework.
    Oncologist. 2026;31:oyag371.
    PubMed    
    Abstract available
    
    

99. LI W, Chen Z, Deng M, Wang S, et al
    Sodium arsenite inhibits ALKBH7 increasing tRNA m(2)(2)G methylation in mitochondrial respiratory chain complex-flankng to drive malignant phenotype of bladder epithelial cells.
    Chem Biol Interact. 2026;439:112326.
    PubMed    
    Abstract available
    
    

100. YAMAMOTO S, Fukata S, Kurano Y, Morishita Y, et al
     Fluorescence-guided local therapy for bladder and upper urinary tract cancer: a narrative review.
     Photodiagnosis Photodyn Ther. 2026;61:105617.
     PubMed    
     Abstract available
     
     

101. MENON A, Koch R, Abramovich C
     Photo Quiz: Globose Yeast-Like Forms With Multiple Peripheral Buds in Urine and Cervical Cytology.
     Diagn Cytopathol. 2026;54:842-845.
     PubMed    
     Abstract available
     
     

102. BUZOIANU MM, Andras I, Vesa S, Giurgiu L, et al
     A single-institutional analysis of laparoscopic 3D radical cystectomy with intracorporeal urinary diversion.
     BMC Urol. 2026;26:238.
     PubMed    
     Abstract available
     
     

103. GUO B, Fu S, Li J, Cheng Q, et al
     An integrative epigenomic and single-cell framework identifies a prognostic DNA methylation risk score and ZNF638 silencing in urothelial carcinoma.
     J Transl Med. 2026;24:1264.
     PubMed    
     Abstract available
     
     

104. ALVAREZ-OSSORIO JL, Alvarez-Maestro M, Cozar-Olmo JM, Espinosa-Bosch M, et al
     Recommendations for the prevention and treatment of adverse effects of intravesical BCG.
     Actas Urol Esp (Engl Ed). 2026;50:502005.
     PubMed    
     Abstract available
     
     

105. LEON P, Long Depaquit T, Audenet F, Allory Y, et al
     Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC.
     Fr J Urol. 2026;36:103156.
     PubMed    
     Abstract available
     
     

106. MATHEZ W, Briche V, Vincentelli A, Bruyere F, et al
     Clinical utility of routine urine culture before intravesical mitomycin C instillation: A retrospective instillation-based study.
     Fr J Urol. 2026;36:103154.
     PubMed    
     Abstract available
     
     

107. MENEGHESSO D, Pasquinucci M, Bruniera M, Carletti F, et al
     Diagnosis by Resolution: Ultrasound Follow-Up of Neonatal Polypoid Cystitis Mimicking Botryoid Rhabdomyosarcoma.
     J Clin Ultrasound. 2026;54:2070-2074.
     PubMed    
     Abstract available
     
     

108. CORBIN H, Khader S, Quiroga-Garza G, Pantanowitz L, et al
     When Small Cells Matter: Diagnosing Bladder Small Cell Carcinoma on Urine Cytology.
     Cytopathology. 2026;37:667-672.
     PubMed    
     Abstract available
     
     

109. KANEKO GO, Igarashi D, Morita M, Tsubota S, et al
     Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma.
     Anticancer Res. 2026;46:5715-5727.
     PubMed    
     Abstract available
     
     

110. FUKUSHIMA H, Yoshida S, Yajima S, Hirakawa A, et al
     Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS.
     Anticancer Res. 2026;46:5729-5735.
     PubMed    
     Abstract available
     
     

111. WAKAMIYA T, Iwagami S, Enyo N, Shibano S, et al
     Structured Symptom Monitoring During Enfortumab Vedotin Plus Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma: Multicenter Retrospective Study.
     Anticancer Res. 2026;46:5639-5650.
     PubMed    
     Abstract available
     
     

112. ESCRIG JLD, Black P, Inokuchi J, Kulkarni G, et al
     Real-world radical cystectomy use in high-risk non-muscle-invasive bladder cancer: a global survey.
     BJU Int. 2026 Oct 2. doi: 10.1111/bju.70480.
     PubMed    
     Abstract available
     
     

113. TOUMAZOS K, Bell S, Spencer K, Nakagawa D, et al
     Patient-reported outcomes as non-muscle-invasive bladder cancer clinical trial endpoints.
     BJU Int. 2026 Sep 28. doi: 10.1111/bju.70461.
     PubMed    
     Abstract available
     
     

114. GUERRERO QUILES C, Abumanhal-Masarweh H, G Abalos J, Lodhi T, et al
     A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer.
     Br J Cancer. 2026 Sep 26. doi: 10.1038/s41416-026-03603.
     PubMed    
     Abstract available
     
     

115. MAENOSONO R, Nishimura K, Tsujino T, Yoshikawa Y, et al
     Multiplex Immunofluorescence-defined CXCL13-associated TLS-like Niches Predict Outcome in Bladder Cancer.
     Clin Cancer Res. 2026 Sep 29. doi: 10.1158/1078-0432.CCR-26-1878.
     PubMed    
     Abstract available
     
     

116. DAVIS LE, Basourakos SP, Calaway AC
     Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2026 Oct 1:S0302-2838(26)01999-8. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

117. DING D, Wei W, Chen H, Tan W, et al
     Reply to Pierre-Etienne Gabriel and Evanguelos Xylinas's Letter to the Editor re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur
     Eur Urol. 2026 Oct 1:S0302-2838(26)02000-2. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

118. SLUSARCZYK A, Uleri A, Radziszewski P, Pradere B, et al
     Re: Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.e
     Eur Urol. 2026 Oct 1:S0302-2838(26)02070-1. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

119. SCILIPOTI P, Montorsi F
     Re: Matthew D. Galsky and Andrea Necchi. Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.07.014.
     Eur Urol. 2026 Sep 26:S0302-2838(26)02418-8. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

120. MOLLICA V, Rosellini M, Santoni M, Massari F, et al
     Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer.
     Eur Urol. 2026 Oct 7:S0302-2838(26)02409-7. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

121. AYDOGDU C, Bukavina L, Cheng L, Al-Ahmadie HA, et al
     Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.
     Eur Urol. 2026;90:377-388.
     PubMed    
     Abstract available
     
     

122. IKEDA R, Yoshida S, Chen W, Fujiwara M, et al
     Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer: A Copula-Based Secondary Analysis.
     Int J Urol. 2026;33:e70667.
     PubMed    
     Abstract available
     
     

123. LEE JH, Lee CU, Song W, Sung HH, et al
     Role of neoadjuvant chemotherapy in micropapillary urothelial carcinoma: a multi-institutional analysis from the Korean Bladder Cancer Research Group.
     Int Urol Nephrol. 2026 Oct 1. doi: 10.1007/s11255-026-05412.
     PubMed    
     Abstract available
     
     

124. HAYASHI Y, Yamashita R, Sakura Y, Sugino T, et al
     Concurrent extension of bladder cancer to the intramural ureter and prostatic urethra increases the risk of urethral cancer in patients undergoing radical cystectomy.
     Int Urol Nephrol. 2026 Sep 26. doi: 10.1007/s11255-026-05408.
     PubMed    
     Abstract available
     
     

125. GAFFNEY CD, Alam SM, Wald G, Sjoberg D, et al
     A Phase I Clinical Trial of Chemoimmunotherapy with Alternating Intravesical Gemcitabine and Bacillus Calmette-Guerin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer.
     J Urol. 2026 Oct 1:101097JU0000000000005324. doi: 10.1097/JU.0000000000005324.
     PubMed    
     Abstract available
     
     

126. DECASTRO GJ, Joffe BI, Stein MN, Abate-Shen C, et al
     A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Nonmuscle-Invasive Bacillus Calmette-Guerin-Unresponsive Urothelial Carcinoma of the Bladder.
     J Urol. 2026;216:676-684.
     PubMed    
     Abstract available
     
     

127. CHANG SS, Chamie K, Seabury CA, Gonzalgo ML, et al
     Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ +/- Papillary Disease.
     J Urol. 2026;216:663-675.
     PubMed    
     Abstract available
     
     

128. TALLMAN JE, Hyman MJ, Agarwal PK, Faris SF, et al
     Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer.
     Urology. 2026 Oct 9:S0090-4295(26)00665-5. doi: 10.1016/j.urology.2026.
     PubMed    
     Abstract available